[Percutaneous treatment for moderate to severe mitral valve insufficiency]
Ventura D, Pichon Riviere A, Alfie V, Mejía J, Latorraca M, Garcia Marti S, Bardach A, Ciapponi A, Alcaraz A, Augustovski F
Record ID 32018013816
Spanish
Original Title:
Tratamiento percutáneo de insuficiencia mitral moderada a severa
Authors' recommendations:
High-quality evidence shows that in patients with moderate or severe mitral valve
insufficiency, who have a high surgical risk, the use of MitraClip® is a valid option with an effectiveness similar to surgical treatment.
High-quality evidence shows that in patients with moderate or severe secondary mitral valve insufficiency who are not eligible for surgery, the use of MitraClip® yields a greater net benefit because it decreases mortality, has lower rates of fatal and non-fatal hospitalizations due to heart failure, fewer hospitalizations due to cardiovascular causes and any cause compared to medical treatment.
Very-low quality evidence from a single observational study showed that in patients who previously underwent surgery due to severe mitral valve insuciency with recurrence of symptoms, there could be a possibility of improvement and low levels of mortality with this percutaneous treatment. No studies comparing MitraClip® with other therapeutic options in this population have been found.
The clinical practice guidelines surveyed recommend the use of MitraClip® in primary and secondary mitral valve insufficiency in symptomatic patients considered inoperable or at high surgical risk by the Cardiology team. They do not mention its use in patients who have previously undergone surgery.
Both private and public funders from the United States of America, as well as funders from high-income countries consulted, provide coverage for patients with primary and secondary mitral valve insufficiency in patients at high surgical risk who are not eligible for surgery.
No economic studies conducted in Argentina or in the region have been found and studies conducted in other countries show contradictory results. Consequently, it is not possible to draw conclusions about its cost-effectiveness.
Details
Project Status:
Completed
Year Published:
2024
URL for published report:
https://ets.iecs.org.ar/publication/2245
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Argentina
MeSH Terms
- Mitral Valve Insufficiency
- Heart Valve Prosthesis
- Heart Valve Prosthesis Implantation
- Cardiac Catheterization
Contact
Organisation Name:
Institute for Clinical Effectiveness and Health Policy
Contact Address:
Dr. Emilio Ravignani 2024, Buenos Aires - Argentina, C1414 CABA
Contact Name:
info@iecs.org.ar
Contact Email:
info@iecs.org.ar
Copyright:
<p>Institute for Clinical Effectiveness and Health Policy (IECS)</p>
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.